BiotechTube
LPOXY Therapeutics

LPOXY Therapeutics

Cambridge, United States· Est.
lpoxy.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

LPOXY Therapeutics is a private, clinical-stage biotech pioneering a novel, non-antibiotic approach to preventing C. difficile infections (CDI) by modulating the gut microenvironment. Its core technology, SIDIPREV™ (LP-102), is an oral capsule that gently increases oxygen tension in the colon, creating an environment hostile to C. difficile growth while sparing the beneficial microbiota. With a $28M Series A financing led by 5 Horizons Ventures, the company is preparing for a pivotal clinical trial (STOP-Cdiff) in high-risk patients, addressing a critical unmet need classified as an 'Urgent' public health threat by the CDC. The platform also holds potential for inflammatory bowel disease.

GastroenterologyInfectious Disease

Technology Platform

SIDIPREV™ - an orally-administered, metered-dose intestinal oxygen delivery system (enteric aerobization) designed to locally modulate the colonic microenvironment.

Opportunities

The lead program addresses a complete unmet need in preventing C.
difficile infection, an 'Urgent' CDC threat with no approved preventive therapies, representing a massive market.
The non-antibiotic, oral mechanism avoids antimicrobial resistance concerns and stewardship hurdles, facilitating adoption.
Platform expansion into the large inflammatory bowel disease market provides a significant long-term growth avenue.

Risk Factors

The novel mechanism faces the inherent risk of failure in the upcoming pivotal clinical trial.
Regulatory pathways for a first-in-class oxygen therapeutic may be complex and uncertain.
The IBD program will eventually face intense competition from established and emerging therapies in a crowded market.

Competitive Landscape

In CDI prevention, LPOXY's SIDIPREV™ appears first-in-class with no direct oral oxygen-delivery competitors; indirect competition includes microbiome-based therapies (e.g., fecal microbiota transplants, live biotherapeutic products) and vaccines in development, which have different mechanisms and challenges. In IBD, the competitive landscape is highly crowded with biologics, small molecules, and other advanced therapies, though an oral, locally-acting oxygen therapy could differentiate on safety and convenience.

More companies in Small Molecule Drugs →More companies in United States →